Held by 5 specialist biotech funds
High Convergence# Signal Note: Rock Springs Capital Initiates PHVS Position Rock Springs' $17.3M entry into Pharvaris suggests conviction in PHVS's lead program, icatibant (a bradykinin B2 receptor antagonist) for hereditary angioedema (HAE).
AI analyst context — unlock full analysis
## Baker Bros. Initiates New Position in Pharvaris (PHVS) **Note: The reported position value of ~$10.4B appears to be a data error—375,000 shares at recent prices (~$27-28) would be worth approximately $10.1-10.5M, which is a modest but notable starter position for Baker Bros.** Baker Bros. opening a new position in Pharvaris is a meaningful signal given their deep biotech specialization and concentrated portfolio style; PHVS's lead asset deucrictibant (PHVS416) is an oral bradykinin B2 receptor antagonist in Phase 3 (CHAPTER-1) for hereditary angioedema (HAE) prophylaxis, with topline data expected in H2 2025—positioning this as a catalyst-driven entry. The HAE prophylaxis market is shifting toward oral
+ 3 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial